Article

Pattern of visual field decline varies by quadrant in POAG

Iowa City-Over a long term, researchers found that in a group of patients with primary open-angle glaucoma (POAG), the average rate of visual field decline (based on the Goldmann I4e isopter) was -1.3% per year.

Related Videos
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
Related Content
Bausch + Lomb voluntarily recalls select enVista IOLs
March 27th 2025

Bausch + Lomb voluntarily recalls select enVista IOLs

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Electroretinography reveals limited duration of dexamethasone implant efficacy in DME
March 27th 2025

Electroretinography reveals limited duration of dexamethasone implant efficacy in DME

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

(Image credit: AdobeStock/iQoncept)
March 26th 2025

Beyond mentoring: The power of sponsorship and advocacy in ophthalmology

Nanoscope Therapeutics publishes clinical data on vision restoration in retinitis pigmentosa
March 26th 2025

Nanoscope Therapeutics publishes clinical data on vision restoration in retinitis pigmentosa

© 2025 MJH Life Sciences

All rights reserved.